Pathogen Access Rules Could Shape Faster, Fairer

What Is the Pathogen Access and Benefit Sharing Annex?

Scientists need timely access to pathogen samples and genetic sequence information to identify emerging threats, develop diagnostic tests and begin evaluating vaccines or treatments. The proposed Pathogen Access and Benefit Sharing system, commonly called PABS, seeks to make that exchange more predictable while recognizing that countries providing biological materials should also benefit from the medical advances those materials help produce.

The annex must translate that principle into operational rules. These may address which pathogens and information are covered, how materials move through participating laboratories, what obligations apply to manufacturers and how benefits such as medical products, laboratory capacity or technical knowledge are shared. Clear definitions will be important because uncertainty could discourage participation or delay research during an outbreak.

Why Does Completing the Annex Matter for Pandemic Preparedness?

Outbreak response depends on linked systems rather than a single intervention. Surveillance detects unusual infections, laboratories characterize the organism, researchers assess medical countermeasures and manufacturers scale up suitable products. Delays or mistrust at any point can weaken the entire chain, particularly when countries are unsure whether sharing pathogen information will lead to meaningful access to the tools developed from it.

A workable PABS framework could establish expectations before an emergency begins. Its public health value will depend on whether it supports rapid scientific exchange without creating excessive administrative barriers and whether promised benefits can be delivered when demand is high. Independent monitoring, transparent procedures and practical arrangements for countries with limited manufacturing or laboratory capacity would strengthen confidence in the system.

Could the Annex Improve Access to Vaccines and Treatments?

Sharing a pathogen does not automatically produce a usable vaccine, diagnostic or medicine. Product development still requires scientific validation, clinical evaluation, regulatory review, manufacturing capacity and reliable supply chains. The annex therefore cannot guarantee that every emerging threat will quickly yield an effective product, but it may clarify how available products and other benefits should be allocated.

Equity also involves more than doses delivered during a crisis. Sustainable laboratory networks, workforce training, regional production, regulatory capacity and access to relevant technology can improve readiness between emergencies. Negotiators will need to balance these longer-term goals with rules that remain simple enough to function when rapid action is medically necessary.